新辅助化疗后乳腺癌残留病灶患者辅助卡培他滨化放疗的可行性与耐受性:一项前瞻性临床试验
该前瞻性单臂试验纳入20例标准新辅助化疗后残留病灶的乳腺癌患者,接受辅助卡培他滨化放疗。18例(90%)按计划完成化放疗,≥3级放射性皮炎发生率为5%(1/20)。患者报告生活质量在化放疗结束时较单纯辅助放疗参考人群出现有临床意义的下降。
要点
- 18例(90%)按计划完成卡培他滨化放疗,达到≥75%的可行性预设标准。
- ≥3级放射性皮炎发生率为5%(1/20患者)。
- 化放疗结束时患者报告生活质量较单纯辅助放疗参考人群有临床意义下降。
核心结论
- 辅助卡培他滨化放疗在乳腺癌患者中可行且可耐受。
- 作者认为这些结果支持在该人群中开展随机试验,以研究卡培他滨同步放疗的疗效,并为试验设计提供患者报告的毒性估计。
研究设计与样本
- 前瞻性单臂试验,纳入20例标准新辅助化疗后残留病灶的乳腺癌患者,接受辅助卡培他滨化放疗。
- 可行性定义为≥75%的患者按计划完成化放疗;毒性采用不良事件通用术语标准5.0版和患者报告放射性皮肤反应量表评估;生活质量采用RAND 36条目简表健康调查评估。
主要发现
- 18例(90%)完成化放疗且未中断或减量。
- ≥3级放射性皮炎发生率为5%(1/20患者)。
- 患者报告放射性皮炎在化放疗后平均增加55分,与已发表的单纯辅助放疗乳腺癌患者平均增加47分相比未显示有临床意义的差异。
- 患者报告生活质量在化放疗结束时平均46(标准差7),较单纯辅助放疗参考人群平均50(标准差6)出现有临床意义的下降。
关键数值与推荐
- 可行性预设标准为≥75%的患者按计划完成化放疗,实际为18例(90%)完成。
- ≥3级放射性皮炎发生率为5%(1/20患者)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Addition of adjuvant capecitabine improves overall survival for patients with breast cancer lacking pathologic complete response to standard-of-care neoadjuvant chemotherapy. Combining radiosensitizing capecitabine concurrent with radiation may further improve disease control, although the feasibility and tolerability of chemoradiation in this setting is unknown. This study aimed to determine the feasibility of this combination. Secondary objectives included the effect of chemoradiation on physician-reported toxicity, patient-reported skin dermatitis, and patient-reported quality of life compared with patients with breast cancer treated with adjuvant radiation. METHODS AND MATERIALS: Twenty patients with residual disease following standard neoadjuvant chemotherapy were enrolled in a prospective single-arm trial and treated with adjuvant capecitabine-based chemoradiation. Feasibility was defined as ≥75% of patients completing chemoradiation as planned. Toxicity was assessed using Common Terminology Criteria for Adverse Events version 5.0 and the patient-reported radiation-induced skin reaction scale. Quality of life was measured using the RAND Short-Form 36-Item Health Survey. RESULTS: Eighteen patients (90%) completed chemoradiation without interruption or dose reduction. The incidence of grade ≥3 radiation dermatitis was 5% (1 of 20 patients). Patient-reported radiation dermatitis did not show a clinically meaningful difference following chemoradiation (mean increase, 55 points) compared with published reports of patients with breast cancer treated with adjuvant radiation alone (mean increase, 47 points). On the other hand, patient-reported quality of life demonstrated a clinically meaningful decline at the end of chemoradiation (mean, 46; SD, 7) compared with the reference population of patients treated with adjuvant radiation alone (mean, 50; SD, 6). CONCLUSIONS: Adjuvant chemoradiation with capecitabine is feasible and tolerable in patients with breast cancer. Although current studies using adjuvant capecitabine for residual disease following neoadjuvant chemotherapy have specified sequential treatment of capecitabine and radiation, these results support the conduct of randomized trials in this setting to investigate the efficacy of concurrent radiation with capecitabine and provide patient-reported toxicity estimates for trial design.
引用
- Balbach ML, Sherry AD, Rexer BN, et al. Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37433376. doi:10.1016/j.ijrobp.2023.06.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。